# Principia SGR

> Principia SGR is a VC fund in Milan backing Health Care and Biotechnology. See 50 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Milan, Italy
- Total investments: 50
- Last investment: Nov 2021
- Lead investor: 40%
- Fund size: $187M
- Last fund: Dec 2014
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/principia-sgr
- X (Twitter): http://twitter.com/principiasgr
- Website: http://www.principiasgr.it
- Facebook: http://www.facebook.com/pages/Principia-SGR/135605003215224

Principia SGR is a VC fund in Milan focused on Health Care and Biotechnology. Principia is an Italian Venture Capital firm with over Eur 80M under management. Currently Principia has two funds investing in digital start ups and expansion capital opportunities and in particular cases, we invest also in seed opportunities.

## Contacts

5 contacts available for Principia SGR. Shizune tracks 3 team members at Principia SGR. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/quantica-sgr?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $329k–$3.3M |
| Series A | $1.5M–$7.7M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 11 | 22% |
| Biotechnology | 10 | 20% |
| Software | 6 | 12% |
| E-Commerce | 5 | 10% |
| Medical Device | 5 | 10% |

77 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 25 | 50% |
| Series A | 11 | 22% |
| Seed | 5 | 10% |
| Series B | 2 | 4% |
| Series C | 2 | 4% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Italy | 30 | 60% |
| United States | 3 | 6% |
| United Kingdom | 3 | 6% |
| France | 2 | 4% |
| Brazil | 1 | 2% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alessandro Damiano | Managing Director, Fund Manager | 0 | https://shizune.co/investors/profile/alessandro-damiano |
| Mariano Ambrosio | Managing Director | 0 | https://shizune.co/investors/profile/mariano-ambrosio |
| Michele Costabile | Managing Director | 2 | https://shizune.co/investors/profile/michele-costabile |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| KLISBio | KLISBio is a clinical-stage regenerative medicine company focused on developing innovative technology platforms based entirely on natural silk fibroin. The company, headquartered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes, rotator cuff repair, drug release, and a first-in-humanstudy on nerve repair that is ongoing at the University of Zurich, Switzerland | $3.4M | Convertible Note | Nov 26, 2021 |  |
| WISE | WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper. | $16.5M | Series C | Oct 01, 2020 |  |
| ENTEROME | Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $51.9M | Series E | Jun 25, 2020 |  |
| COMPASS Pathways | Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression.Compass Pathways conducts clinical trials and research toassess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression. | $32.7M | Series A | Oct 03, 2018 |  |
| ComfTech s.r.l. | ComfTech design and produce sensing garments easy to dress and use for continuous non-intrusive monitoring of biomedical parameters. Comftech smart garments enable accurate measurement of a range of physiological parameters and offer reliable, continuous and non-invasive monitoring.Comftech products have been conceived in close collaboration withdoctors and nurses. The guidelines delineated a product which is highly technological, but keeping well in mind that the final solution should be absolutely comfortable and simple to be used by the newborn, the family members and by the medical and paramedical staff.The results have been enthusiastically receveid by nurses, doctors, and families alike: this opportunity allowed us to carry out a thorough analysis researching the opportunities of such a concept in the child's monitoring market, the technological feasibility and all the industrial organizational aspects. | $7.7M |  | Aug 06, 2018 |  |
| Crest Optics | Crisel Electrooptical Systems & Technology has been created by a team of people with a long and proven experience in scientific research, industrial design and manufacturing of electrooptical systems.Mission of the company is the production of state of art instruments using optical and electrooptical technology for scientific and industrialapplications, key target areas are: fluorescence microscopy and spectroscopy.The company is located in Roma – Italy, which means we can take advantage of the many world renowned Research Institutions existing in the area, in fact we are already working on joined research project with CNR – FISBAT on the development of new technologies for fluorescence microscopy on live cells and laser activated experiments.CrEST is also taking advantage of Crisel Instruments (CrEST partner company) thorough knowledge of biology applications and market, due to more than 15 years of activity in integration and sales of live cell imaging systems in the Italian market. | $7.2M |  | Jul 08, 2018 |  |
| ENTEROME | Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $43.9M | Debt Financing | Jan 04, 2018 |  |
| Clinical Trial Center S.P.A. | Clinical Trial Center S.P.A. offers clinic research and trial services. |  |  | Aug 12, 2017 |  |
| WISE | WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper. | $7.1M | Series B | May 25, 2017 |  |
| ENTEROME | Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $35.1M | Series D | Jan 01, 2017 |  |

10 of 50 investments shown.

## Co-investors
- [Atlante Seeds](https://shizune.co/investors/profile/atlante-seeds) — VC Fund, 4 deals together
- [dPixel](https://shizune.co/investors/profile/dpixel) — VC Fund, 4 deals together
- [Atlante Ventures](https://shizune.co/investors/profile/atlante-ventures) — VC Fund, 3 deals together
- [Health for Life Capital fund](https://shizune.co/investors/profile/health-for-life-capital-fund) — VC Fund, 3 deals together
- [Nestlé Health Science](https://shizune.co/investors/profile/nestl-health-science) — VC Fund, 3 deals together
- [Omnes Capital](https://shizune.co/investors/profile/omnes-capital) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [CDP Venture Capital](https://shizune.co/investors/profile/cdp-venture-capital) — VC Fund
- [Club degli Investitori](https://shizune.co/investors/profile/club-degli-investitori) — VC Fund
- [Primo Capital](https://shizune.co/investors/profile/barcamper-ventures) — VC Fund

## Featured in investor lists
- [All Investors in Italy](https://shizune.co/investors/investors-italy)
- [All VC Funds in Italy](https://shizune.co/investors/vc-funds-italy)
- [SaaS Investors in Italy](https://shizune.co/investors/saas-investors-italy)
- [SaaS VC Funds in Italy](https://shizune.co/investors/saas-vc-funds-italy)
- [Software VC Funds in Italy](https://shizune.co/investors/software-vc-funds-italy)
- [Enterprise Investors in Italy](https://shizune.co/investors/enterprise-investors-italy)

## FAQ

### What does Principia SGR invest in?

Principia SGR invests primarily in Health Care, Biotechnology and Software startups, most often at Funding Round and Series A stage. Most of the 50 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Principia SGR's check size?

Principia SGR typically joins rounds of $329k–$3.3M at Seed and $1.5M–$7.7M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Principia SGR participates in.

### How do I contact Principia SGR?

Public channels for Principia SGR include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Principia SGR?

The team at Principia SGR includes Alessandro Damiano (Managing Director, Fund Manager), Mariano Ambrosio (Managing Director) and Michele Costabile (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co